$133 million Series B financing co-led by new investors Advent Life Sciences and British Business Bank, with additional new investments from Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Samsara BioCapital, M-Ventures and Lilly, joined by all existing major shareholders

由新投资者Advent Life Sciences和英国商业银行（British Business Bank）联合领投的1.33亿美元B轮融资，并获得强生创新旗下JJDC公司（JJDC）、Samsara BioCapital、M-Ventures以及礼来公司的额外新投资，所有现有主要股东均参与跟投。

Proceeds to fund two first-in-class TCR-CD3 bispecific programmes in cancer and autoimmune disease through to clinical proof-of-concept

资助两个针对癌症和自身免疫性疾病的同类首创TCR-CD3双特异性项目，直至完成临床概念验证

Dr. Kirsty Crame appointed Chief Development Officer to oversee translational and clinical development of the company’s bispecific programmes

Kirsty Crame 博士被任命为首席开发官，负责监督公司双特异性项目从转化研究到临床开发的各项工作

5

5

th

泰国

November 2026

2026年11月

;

分号

Cambridge, UK

英国剑桥

–

–

T-Therapeutics

T-疗法公司

, a biotechnology company developing next-generation T cell receptor (TCR) T cell engager (TCE) therapeutics for cancer and autoimmune diseases, today announces the closing of an oversubscribed $133 million Series B financing to fund the clinical development of its first-in-class TCR-CD3 bispecific lead programmes in oncology and autoimmune disease..

，一家致力于开发用于癌症和自身免疫性疾病的下一代T细胞受体（TCR）T细胞衔接器（TCE）疗法的生物技术公司，今日宣布完成超额认购的1.33亿美元B轮融资，以资助其在肿瘤学和自身免疫性疾病领域的首创类TCR-CD3双特异性领先项目的临床开发。

The financing was co-led by Advent Life Sciences and British Business Bank with participation from other new investors, JJDC, Samsara BioCapital, M-Ventures and Eli Lilly and Company (Lilly), alongside all existing major shareholders, Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, Tencent and BGF..

本轮融资由Advent Life Sciences和英国商业银行联合领投，其他新投资者JJDC、Samsara BioCapital、M-Ventures以及礼来公司（Lilly）参与投资，同时所有现有主要股东Sofinnova Partners、F-Prime、Digitalis Ventures、Cambridge Innovation Capital、Sanofi Ventures、腾讯和BGF也继续跟投。

Proceeds from the financing will support entry into the clinic and the generation of clinical proof-of-concept data for T-Therapeutics’ two lead programmes in cancer and autoimmune diseases. Both programmes leverage the company’s unique, proprietary OpTiMus® platform, which provides an unparalleled supply of fully human TCRs, enabling access to validated, but previously undruggable, intracellular targets..

融资所得将用于支持T-Therapeutics公司在癌症和自身免疫性疾病领域的两个核心项目进入临床试验阶段，并生成临床概念验证数据。这两个项目均依托公司独有的OpTiMus®平台，该平台能够提供无与伦比的全人源T细胞受体（TCR）资源，从而使得针对已验证但此前无法成药的细胞内靶点的药物开发成为可能。

T-Therapeutics’ lead oncology programme offers broad therapeutic potential across the largely untapped solid tumour space. In immunology, the company is deploying its platform to drive a novel, precision approach to immune reset, through the selective depletion of pathogenic cells that drive chronic tissue inflammation.

T-Therapeutics 的核心肿瘤学项目在 largely 未开发的实体瘤领域展现出广泛的治疗潜力。在免疫学领域，该公司正利用其平台推动一种新型的精准免疫重置方法，通过选择性清除导致慢性组织炎症的致病细胞来实现这一目标。

Both programmes have the potential to address multiple indications and to meaningfully improve patient outcomes where there are currently limited treatment options..

这两个项目均有潜力针对多种适应症，并在目前治疗选择有限的情况下显著改善患者预后。

Following this financing, representatives from Advent Life Sciences, British Business Bank, JJDC and Samsara BioCapital will join T-Therapeutics’ Board as non-executive directors.

在此轮融资之后，来自Advent Life Sciences、英国商业银行（British Business Bank）、JJDC和Samsara BioCapital的代表将作为非执行董事加入T-Therapeutics的董事会。

Alongside the Series B financing, T-Therapeutics has further strengthened its leadership team with the appointment of Dr. Kirsty Crame as Chief Development Officer to oversee the translational and clinical development of the company’s pipeline. Dr. Crame previously served as Chief Medical Officer at Curatis AG and brings over 15 years’ experience in novel biopharmaceutical development.

在完成B轮融资的同时，T-Therapeutics通过任命Kirsty Crame博士为首席开发官，进一步强化了其领导团队。Crame博士将负责监督公司产品管线的转化研究与临床开发。她此前曾担任Curatis AG的首席医学官，拥有超过15年的新型生物制药开发经验。

She led multiple early-stage clinical programmes at Medigene AG and Gadeta BV, and has particular expertise in TCR-based therapeutics..

她在Medigene AG和Gadeta BV领导了多个早期临床项目，并在基于TCR的治疗领域拥有专长。

Theodora Harold, Chief Executive Officer of T-Therapeutics, said:

T-Therapeutics 首席执行官西奥多拉·哈罗德表示：

“This financing is a key step in our transition to a clinical-stage company, enabling us to accelerate the development of two oncology and immunology programmes with pan-indication, blockbuster potential, underpinned by a platform that reaches targets long considered undruggable. The further strengthening of our team with the appointment of Dr.

“此次融资是我们向临床阶段公司转型的关键一步，使我们能够加速推进两个具有泛适应症和重磅药物潜力的肿瘤学和免疫学项目，这些项目依托于一个能够作用于长期以来被认为不可成药的靶点的平台。随着博士的任命，我们的团队得到进一步加强。”

Kirsty Crame, and the proceeds from this raise, position us well for rapid execution of those programmes and the delivery of important clinical proof-of-concept data. My thanks to our new and longstanding investors, whose confidence in our science enables a next generation of T cell engager therapeutics.”.

Kirsty Crame 表示，此次融资所得款项使我们处于有利地位，能够快速推进这些项目的执行，并交付重要的临床概念验证数据。她感谢新老投资者，正是他们对我们科学研究的信心，推动了下一代 T 细胞衔接器疗法的开发。

Dominic Schmidt, General Partner at Advent Life Sciences, added:

Advent Life Sciences 的普通合伙人多米尼克·施密特补充道：

“T cell engagers have delivered clinical success in haematological cancers but have been held back in solid tumours by the lack of appropriate targets. By unlocking previously undruggable intracellular targets, with the potential for a markedly improved safety profile, T-Therapeutics' platform brings the promise of this treatment/modality to solid tumours, where the great majority of cancers arise.”.

“T细胞衔接器在血液系统恶性肿瘤中已取得临床成功，但因缺乏合适的靶点而在实体瘤领域进展受阻。通过解锁此前无法成药的细胞内靶点，并有望显著改善安全性，T-Therapeutics的技术平台将这种治疗模式的应用前景拓展至实体瘤，而绝大多数癌症均起源于实体瘤。”

Dr. Kirsty Crame, newly appointed Chief Development Officer of T-Therapeutics, said:

T-Therapeutics新任首席开发官Kirsty Crame博士表示：

“I am delighted to join T-Therapeutics at this pivotal moment for the Company. I look forward to advancing our clinical strategy and first-in-class programmes, and to realising the potential of our platform technologies to address major therapy areas with significant unmet patient need.”

“我很高兴在公司发展的关键时期加入T-Therapeutics。我期待推进我们的临床战略和首创疗法项目，并充分发挥我们平台技术的潜力，以应对存在重大未满足患者需求的主要治疗领域。”

Contact Us

联系我们

T-Therapeutics

T-疗法公司

Theodora Harold

西奥多拉·哈罗德

info@t-therapeutics.com

info@t-therapeutics.com

ICR Healthcare

ICR 医疗

Amber Fennell, David Daley, Phillip Marriage

安珀·芬内尔，大卫·戴利，菲利普·马里奇

t-therapeutics@icrhealthcare.com

t-therapeutics@icrhealthcare.com

About T-Therapeutics

关于 T-Therapeutics

T-Therapeutics is a next-generation T cell receptor (TCR) T cell engager (TCE) company developing novel therapeutics. The company harnesses T cell biology to create safe and effective treatments for cancer and autoimmune diseases. The company is developing a pipeline of first-in-class, pan-indication drugs that are intended to become transformative medicines, reshaping the clinical landscape for patients..

T-Therapeutics 是一家下一代 T 细胞受体（TCR）T 细胞衔接器（TCE）公司，致力于开发新型疗法。该公司利用 T 细胞生物学原理，为癌症和自身免疫性疾病创造安全有效的治疗方法。公司正在开发一系列首创的、适用于多种适应症的药物，旨在成为变革性药物，重塑患者的临床治疗格局。

The Company is backed by expert, specialist healthcare investors Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, University of Cambridge Venture Fund, Tencent, BGF, Advent Life Sciences, British Business Bank, JJDC, Samsara BioCapital, M-Ventures, and Lilly..

该公司由以下专业医疗健康领域投资者支持：Sofinnova Partners、F-Prime、Digitalis Ventures、Cambridge Innovation Capital、Sanofi Ventures、剑桥大学风险投资基金、腾讯、BGF、Advent Life Sciences、英国商业银行（British Business Bank）、JJDC、Samsara BioCapital、M-Ventures 以及礼来公司（Lilly）。